Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts

According to recent epidemiological data, 2.3% of the population aged over 65 years in Europe is suffering from neovascular (wet) age-related macular degeneration (wAMD), with the disease posing a significant public health problem [1‐3]. wAMD is diagnosed less often than dry AMD, yet it accounts for 90% of severe vision loss cases [1, 2].

During the past decade, new targeted treatments against vascular endothelial growth factor (anti-VEGF agents) have been introduced in the management of wAMD patients changing the visual prognosis in these patients [4]. A large benefit in vision of patients treated with ranibizumab was initially highlighted in large multicenter trials, followed by the use of bevacizumab and recently aflibercept [5‐9]. Moreover, diagnostic technologies, and especially optical coherence tomography (OCT) have revolutionized the AMD diagnosis and treatment algorithm [10]. However, despite positive developments in disease management, there are no commonly accepted therapeutic response evaluation criteria. This is particularly true when the discussion is not limited to patients that are selected based on criteria similar to those in large clinical trials, but when referring to the individual patient, treated by an ophthalmologist in everyday clinical practice. In addition, there is ongoing research for parameters predictive or suggestive of no response to anti-VEGF therapy since the characteristics of patients not responding to treatment are not clearly defined. Thus, deriving the maximum possible benefit for each individual patient in the clinic becomes more difficult.

The purpose of this article is to present guidelines, compiled by a panel of specialized ophthalmologists in the area of wAMD, and propose commonly accepted therapeutic response criteria and define treatment discontinuation criteria for patients suffering from wAMD treated with anti-VEGF agents.

A team of Greek retina experts developed a consensus paper after three consecutive meetings. The expert panel reviewed the peer-reviewed literature with the goal to establish practical guidelines for the practicing ophthalmologist. The group was focused on guidelines to help clinical decision-making around the definition of successful treatment and the definition of non-response to therapy. This article does not contain any new studies with human or animal subjects performed by any of the authors.

Prior to treatment initiation, compliance with the examination algorithm depicted in Fig. 1 is suggested. It is important to establish an initial diagnosis of wAMD before initiating treatment. Naturally, signs of the disease include central vision loss and metamorphopsia. Family history of AMD as well as social habits like smoking is important and should be recorded. Concomitant disease, e.g., arterial hypertension or diabetes mellitus should also be recorded. At baseline, it is expected that best corrected visual acuity (BCVA), dilated fundus examination, fluorescein angiography and optical coherence tomography (OCT) should be performed in order to confirm the diagnosis of wAMD and establish baseline criteria for evaluation of the treatment effect. Indocyanine green angiography (ICG) is not performed routinely. Ιt is, however, indicated in those patients where choroidal neovascularization (CNV) due to other etiologies is suspected and needs to be ruled out. The differential diagnosis from chronic central serous chorioretinopathy, retinal angiomatous proliferation (RAP) and polypoidal choroidal vasculopathy (PCV) is important also due to their different prognosis and treatment strategy [11‐14].

After initiation of treatment, three monthly injections are advised. The frequency of follow-up and criteria for treatment administration thereafter depends on the treatment scheme that is adopted (monthly, pro re nata or treat and extend strategy, etc.). Follow-up is based on the evaluation of functional and morphological parameters to assess disease activity.

Various dosage schemes have been offered to patients given the real-life limitations that a costly and intensive treatment scheme of fixed monthly injections can encounter in practice. Results from the use of less intensive dosing schemes of ranibizumab, bevacizumab and aflibercept, coming from PIER (Clinicaltrials.gov identifier, NCT00090623), PrONTO (NCT00344227), SECURE (NCT00504959), HARBOR (NCT00891735), AURA (NCT01447043), CATT (NCT00593450), IVAN (ISRCTN92166560) and CLEAR-IT2 (NCT00320788) have been generally variable and inferior to monthly dosing; however, the pro re nata dosing regimen is commonly used in practice [7‐9, 15‐19].

Visual acuity constitutes the main functional parameter for quantitative evaluation of functional response in the treatment of wAMD and the main criterion that influences clinical decision-making. Tests to assess function are of primary importance, since they try to measure the loss that the patient experiences in life. Additional psychophysical methods such as contrast sensitivity and microperimetry may be used as ancillary methods, but are not usually part of the clinic routine (Table 1). Near visual acuity is also important. Standardized testing of BCVA with Early Treatment Diabetic Retinopathy Study (ETDRS) charts helps reduce variability that is associated with the measurement of this parameter. Identical procedures should ideally be followed in every visit.

Changes in visual symptoms and in patient’s subjective complaints regarding vision should be recorded. Any level of vision improvement in a wAMD patient may be defined in effect as a positive outcome. Vision loss that does not exceed 5–10 EDRTS letters (1–2 Snellen lines) can also be considered an outcome that is better compared to the natural history of the disease. Left untreated, the CNV lesion will grow to involve the fovea and cause more profound vision loss.

In reality, the minimum visual benefit for the patient would be to sustain vision loss that is less compared to that if left untreated, according to the natural history of the disease. The natural history of the disease has been documented in several studies and also supported by findings in untreated eyes in the Macula Photocoagulation Study (Clinicaltrials.gov identifier, NCT00000158) [20‐23]. The results from the large scale, carefully conducted, multicenter, randomized controlled clinical trials can also be used to reveal the natural history of the disease, where comparisons are made against the placebo arm. Measurement variability and uncertainty exists in trials and clinical practice as well. Results from the MARINA study (Clinicaltrials.gov identifier, NCT00056836) indicated a 2-year loss of 14.9 ETDRS letters in the sham injection group [24]. In the ANCHOR study (Clinicaltrials.gov identifier, NCT00061594), a loss of 9.5 letters with verterporfin at 12 months was reported [6]. The PIER study found a mean loss of 16.3 ETDRS letters in 1 year [9]. A recent meta-analysis of the literature also supports a mean decrease of 4 lines in visual acuity at 24 months [25]. It is also recognized that the visual gain is dependent on starting visual acuity and there is also a ceiling effect when exploring results in patients with good starting BCVA. There is also a floor effect in cases of low visual acuity, highlighting the limitations in looking only at the change in the number of letters, without taking into consideration the starting BCVA. However, in order to provide a recommendation for use in clinical practice, the panel ascribed any level of visual gain or a loss that is less than 10 ETDRS letters as a response that is better than the natural history of the disease.

Morphological evidence of the disease status is essential, since it often precedes functional deficit and it can alert the physician as to the disease activity.

In general, structure and function do not correlate very well and are supposed to provide different information on the disease status [26]. This disconnect between structure and function has long been recognized and attempts have been made in order to propose morphological parameters that could predict the functional outcome [27]. In fact, morphological signs of disease activity on OCT, are given primary importance since they correspond to early signs of recurrence, usually observed before BCVA loss [28]. Moreover, it has been recognized that anatomic parameters at baseline may also carry prognostic information, with foveal intraretinal fluid being associated with worse visual outcome and subretinal fluid interestingly, being associated with better visual outcome [29, 30].

Table 2 depicts the main anatomic parameters taken into consideration. Their evaluation is performed based on spectral domain-OCT scans.

Techniques, such as angiography and autofluorescence are particularly important in special circumstances (Table 3). Angiography is also useful in case of recurrence. Otherwise, OCT has emerged as the most useful tool to provide evidence of morphological response to treatment or signs of recurrence. Parameters that are important to monitor on OCT are central retina thickness (CRT), presence of subretinal fluid (SRF) or intraretinal fluid, the anatomy of the outer retina layers and the presence and extent of pigment epithelial detachment (PED). Most of these parameters can quantitatively measure the efficacy of the treatment regimen.

Response to treatment is evaluated based on anatomic and functional criteria. Anatomic criteria can provide qualitative and quantitative information. Based on anatomic parameters, a positive outcome of a therapeutic intervention is defined as:

It is a recognized fact that not all patients respond to treatment. Nine percent and 10% of patients treated in the MARINA and ANCHOR trials with monthly ranibizumab experienced a loss in BCVA of more than 15 letters at 2 years [24]. The definition of non-response to treatment is based on the findings described below from functional and anatomic parameters. However, it is understood that ongoing visual acuity loss may in fact result from the development of scarring or geographic atrophy in the center of the fovea, and not only from non-response to the administered anti-VEGF treatment [32]. Therefore, anatomic signs of ongoing wAMD activity should in fact be carefully taken into account to support non-response to anti-VEGF therapy.

In the case of a patient that fulfills the below-mentioned criteria, (s)he is characterized as non-responder and may discontinue anti-angiogenetic factor treatment:

Patients that already sustained profound central vision loss in the other eye should probably be treated individually, having a lower threshold for administering treatment. These patients are already at a higher risk of developing wAMD in the fellow eye, therefore close monitoring and timely treatment is indicated [45‐47].

The purpose of this paper is to provide a consensus document concerning functional and anatomic criteria used in the evaluation of anti-VEGF treatment response and treatment discontinuation, as a guide in everyday clinical practice regarding the optimal treatment of wAMD. It has already been a decade since the FDA and EMA approval of ranibizumab in the United States and Europe for all wAMD lesion types and recently, a second drug, aflibercept, has been approved [5, 8]. It is true that intravitreal anti-angiogenetic treatment has changed the prognosis for patients with wAMD [48, 49]. Therefore, it is important to determine qualitative and quantitative criteria that can characterize a patient’s response to treatment [31, 50, 51].

Real-world studies have generally been associated with inferior outcomes, compared to those reported in the pivotal trials [52]. It is recognized that the clinical situations and variations that arise in clinical practice are not identical to those met in the well-designed clinical trials that led to the introduction of the drugs. Moreover, patients are generally harder to adhere to the intensive monitoring and treatment scheme in clinical practice. Importantly, early diagnosis and initiation of treatment are essential for a successful outcome. Compliance with treatment is another crucial factor. It is currently believed that initiation of anti-VEGF therapy should not be delayed to ensure that anatomical signs of activity are short lived and that chronic changes have not already damaged the photoreceptor layer [28]. Success has also been variable with different treatment schemes to ensure the same outcome can be achieved with less-than-monthly dosing used in the pivotal ranibizumab trials. Efforts oriented to improve patient compliance with treatment schedule are advocated.

Additionally, knowledge around genetic factors that appear to be important factors controlling response to anti-VEGF treatment is also emerging. Interestingly, low-risk complement factor H phenotypes may in fact predict a favorable response compared to the high-risk group [53]. It remains, however, unknown how this increasing knowledge can translate in clinical practice and whether it will change our treatment approach.

Advances in imaging modalities have definitely revolutionized diagnosis and follow-up of wAMD. OCT has emerged as an essential tool in the care of patients with wAMD nowadays. Fundus autofluorescence imaging and indocyanine green angiography provide useful information in selected cases. It remains to be seen how advances in OCT angiography will change the approach to diagnosis and treatment in those patients.

Morphological evidence of disease activity is crucial, since it provides objective information and can earlier detect activity or recurrence. Fibrosis resulting in permanent disruption of tissue architecture and loss of the outer layers cause irreversible loss of central vision. Therefore, treatment of the lesion before permanent damage has occurred is essential. Finally, progression of atrophy should be carefully observed during prolonged treatment, since it represents an important factor in determining visual outcome [54]. Given the chronic nature of the disease, future studies may further highlight factors that are important for the long-term visual prognosis of the individual wAMD patient.